**Global divergence from WHO treatment guidelines for neonatal and paediatric sepsis**

Charlotte Jackson PhD1\*, Yingfen Hsia PhD1, Romain Basmaci MD PhD2,3, Julia Bielicki MD1,4, Paul T. Heath FRCPCH1, Ann Versporten MPH5, Herman Goossens PhD5, Mike Sharland MD1

1 Paediatric Infectious Diseases Research Group, Institute of Infection and Immunity, St George’s, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom

2 Service de Pédiatrie-Urgences, Hôpital Louis-Mourier, APHP, 178 rue des Renouillers, 92700 Colombes, France

3 INSERM, Infection, Antimicrobiens, Modélisation, Evolution (IAME), UMR1137, Université Paris Diderot - Sorbonne Paris Cité, 16 rue Henri Huchard 75890 Paris Cedex 18, Paris, France

4 Paediatric Pharmacology and Paediatric Infectious Diseases, University Children's Hospital Basel,

Spitalstrasse 33, 4056 Basel, Switzerland

5 Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium

\* Corresponding author (current address):

Dr Charlotte Jackson

MRC CTU at UCL

90 High Holborn (2nd floor)

WC1V 6LJ

United Kingdom

Tel: +44 (0)20 8725 2780

Email: c.r.jackson@ucl.ac.uk

*Sources of support*

GARPEC was funded by the PENTA Foundation.

bioMérieux provided unrestricted funding support for the Global-PPS.

*Key words*

Sepsis

Antibiotics

Neonates

Children

*Abbreviated title*

Treatment of neonatal and paediatric sepsis

*Running head title*

Treatment of neonatal and paediatric sepsis

*Disclosures*

Dr Bielicki’s husband is a senior corporate counsel at Novartis International AG (Basel, Switzerland) and holds Novartis stock and stock options. All other authors declare no competing interests.